Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15262698 | 0.87 | CA1 (0.32) | GAA | |
| SCHEMBL20796923 | 0.82 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20393903 | 0.80 | GAA (0.36) | GAAMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL19368108 | 0.80 | GAA (0.43) | GAAMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL22563662 | 0.79 | GAA (0.35) | GAACYP1A2SMN1; SMN2 | |
| SCHEMBL28844439 | 0.79 | GAA (0.36) | GAAMAPTCYP1A2ALDH1A1L3MBTL1 | |
| SCHEMBL19368110 | 0.76 | GAA (0.43) | GAAMAPTCYP1A2L3MBTL1SMN1; SMN2 | |
| SCHEMBL22563657 | 0.75 | GAA (0.33) | GAA | |
| SCHEMBL19368113 | 0.75 | GAA (0.33) | GAAMAPTL3MBTL1 | |
| SCHEMBL12156992 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119213585-A | Electrode for lithium ion battery and lithium ion battery | 住友精化株式会社 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| EP-3726636-B1 | ELECTROLYTE SOLUTION FOR NONAQUEOUS ELECTROLYTE BATTERIES AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | CENTRAL GLASS CO LTD (JP) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023234016-A1 | ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | 住友精化株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023234017-A1 | LITHIUM-ION BATTERY ELECTRODE AND LITHIUM-ION BATTERY | 住友精化株式会社 | 2023-12-07 | — | — | WO | disclosed |
| CN-110383565-B | Additive for nonaqueous electrolyte solution, and electricity storage device | 住友精化株式会社 | 2022-08-23 | — | — | CN | disclosed |
| US-11342587-B2 | Additive for non-aqueous electrolytic solutions, non-aqueous electrolytic solution, and electrical storage device | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-11038201-B2 | Additive for nonaqueous electrolyte solutions, nonaqueous electrolyte solution, and electricity storage device | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20210119255-A1 | NON-AQUEOUS ELECTROLYTE FOR POWER STORAGE DEVICE, AND POWER STORAGE DEVICE | MU IONIC SOLUTIONS CORPORATION (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200335823-A1 | Electrolyte Solution for Nonaqueous Electrolyte Batteries and Nonaqueous Electrolyte Battery Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
| EP-3726636-A1 | ELECTROLYTE SOLUTION FOR NONAQUEOUS ELECTROLYTE BATTERIES AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | Central Glass Company, Limited (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3667802-A1 | ADDITIVE FOR NON-AQUEOUS ELECTROLYTE, NON-AQUEOUS ELECTROLYTE, AND POWER STORAGE DEVICE | Sumitomo Seika Chemicals Co. Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20200036040-A1 | ADDITIVE FOR NON-AQUEOUS ELECTROLYTIC SOLUTIONS, NON-AQUEOUS ELECTROLYTIC SOLUTION, AND ELECTRICAL STORAGE DEVICE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-10320032-B2 | Organic electrolytic solution and lithium battery using the same | SAMSUNG SDI CO., LTD. (KR) | 2019-06-11 | — | — | US | disclosed |
| EP-3349290-A1 | ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND ELECTRICITY STORAGE DEVICE | Sumitomo Seika Chemicals Co. Ltd. (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20170271715-A1 | ORGANIC ELECTROLYTIC SOLUTION AND LITHIUM BATTERY USING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2017-09-21 | — | — | US | disclosed |
| US-20170271715-A1 | ORGANIC ELECTROLYTIC SOLUTION AND LITHIUM BATTERY USING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10320032-B2 | Organic electrolytic solution and lithium battery using the same | OXSR1, OR10J3, CLIC1 | GAA 4342/4885MAPT 4014/4885CYP1A2 1878/4885 |
| US-11038201-B2 | Additive for nonaqueous electrolyte solutions, nonaqueous electrolyte solution, and electricity storage device | SLC9A1, KCNN1, HCN1 | GAA 3985/4885MAPT 4767/4885CYP1A2 2382/4885 |
| US-20210119255-A1 | NON-AQUEOUS ELECTROLYTE FOR POWER STORAGE DEVICE, AND POWER STORAGE DEVICE | SCNN1A, NCLN, HCN2 | GAA 4560/4885MAPT 4530/4885CYP1A2 3163/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | GAA 4638/4885MAPT 4878/4885CYP1A2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.